Jefferies Group’s Vir Biotechnology VIR Stock Holding History

Jefferies Group’s Portfolio VIR Stock Details VIR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q1	–	Sell	-45,000	Closed	-$1.21M	–	2018
2020 Q4	$1.21M	Buy	+45,000	New	+$1.46M	0.01%	875

Other funds holding VIR

SIAU

SB Investment Advisers (UK) London, United Kingdom $7.66B AUM 20.12% 1-Year Est. Return

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Temasek Holdings Singapore $37.3B AUM 12.6% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return

APF

Alaska Permanent Fund Juneau, Alaska $1.51B AUM 22.23% 1-Year Est. Return

Gates Foundation Seattle, Washington $43.5M AUM 14.19% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

AllianceBernstein Nashville, Tennessee $302B AUM 26.44% 1-Year Est. Return

Jefferies Group's VIR Position: Q1 2021 in Review

Jefferies Group sold out of Vir Biotechnology (VIR) in Q1 2021, closing a stake of 15,000 shares — an estimated $402K sold.

Jefferies Group first reported a position in VIR in Q4 2020 and held it in 1 quarter. The position peaked at $402K in Q4 2020. 157 funds tracked by Wall St. Rank hold VIR as of Q1 2021.

Jefferies Group reported no remaining Vir Biotechnology position as of Q1 2021 after selling out during the quarter.
Jefferies Group sold 15,000 Vir Biotechnology shares in Q1 2021, an estimated $402K.
Jefferies Group first reported a position in Vir Biotechnology in Q4 2020 and held it in 1 quarter.
Jefferies Group's Vir Biotechnology position peaked at $402K in Q4 2020.
157 funds tracked by Wall St. Rank held Vir Biotechnology as of Q1 2021.

Based on Jefferies Group's 13F filing for Q1 2021, filed 14 May 2021.